Where Can I Get Compounded Tirzepatide? The Complete 2026 Access Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide requires a valid prescription from a licensed provider and must be dispensed by a state-licensed 503A or 503B compounding pharmacy
• Three legal pathways exist: telehealth platforms with in-house pharmacy networks, standalone compounding pharmacies accepting outside prescriptions, and provider offices with direct pharmacy relationships
• The FDA tirzepatide shortage designation (active as of April 2026) makes compounding legal under federal law, but state regulations vary significantly
• Costs range from $299 to $599 per month depending on dose, pharmacy type, and whether the platform bundles provider visits with medication

Direct answer (40-60 words)

You can get compounded tirzepatide through three legal channels: telehealth platforms that connect you with both a prescriber and a compounding pharmacy (like FormBlends), standalone 503A or 503B compounding pharmacies that accept prescriptions from your existing provider, or directly through weight-loss clinics with in-house compounding relationships. All require a valid prescription.

Table of contents

1. The three legal pathways to compounded tirzepatide
2. What most articles get wrong about compounding pharmacy access
3. Telehealth platforms: the fastest route for most patients
4. Standalone compounding pharmacies: when you already have a prescription
5. Provider offices with direct pharmacy relationships
6. The FDA shortage list and why it matters for access
7. State-by-state restrictions you need to know
8. Cost comparison across all three pathways
9. The decision tree: which pathway matches your situation
10. Red flags that indicate an illegal or unsafe source
11. What happens if the FDA removes tirzepatide from the shortage list
12. FAQ
13. Sources

The three legal pathways to compounded tirzepatide

Compounded tirzepatide is not available over-the-counter, through retail pharmacies like CVS or Walgreens, or without a prescription. Federal law requires that compounded medications be prescribed by a licensed healthcare provider and dispensed by a pharmacy operating under either 503A (traditional compounding pharmacy) or 503B (outsourcing facility) regulations.

The three legal pathways:

Pathway 1: Telehealth platforms with integrated pharmacy networks. These platforms (FormBlends, and others) provide both the medical consultation and the medication fulfillment. You complete an online intake, a licensed provider reviews your case and writes a prescription if appropriate, and the prescription is sent to the platform's partner compounding pharmacy. The medication ships directly to you. Typical timeline: 3 to 7 days from intake to delivery.

Pathway 2: Standalone compounding pharmacies accepting outside prescriptions. If you already have a prescription for tirzepatide from your primary care provider, endocrinologist, or weight-loss specialist, you can take that prescription to a 503A or 503B compounding pharmacy that compounds tirzepatide. Not all compounding pharmacies offer GLP-1 peptides, so you'll need to call ahead. Typical timeline: 1 to 3 days once the prescription is received.

Pathway 3: Provider offices with direct pharmacy relationships. Some weight-loss clinics, med spas, and concierge medicine practices have exclusive relationships with specific compounding pharmacies. You see the provider in-person or via telemedicine, and the practice coordinates fulfillment through their partner pharmacy. The medication may be dispensed on-site or shipped. Typical timeline: same-day to 5 days.

All three pathways are legal under current FDA guidance, provided the tirzepatide shortage remains active and the pharmacy is properly licensed.

What most articles get wrong about compounding pharmacy access

Most online guides state that "any compounding pharmacy can fill a tirzepatide prescription." That's technically true but practically misleading.

As of April 2026, fewer than 15% of the approximately 7,500 compounding pharmacies in the U.S. actually compound tirzepatide. The reasons:

• Sourcing complexity. Tirzepatide API (active pharmaceutical ingredient) is not widely available. Pharmacies must establish relationships with FDA-registered suppliers and verify certificates of analysis for every batch. Many small compounding pharmacies lack the infrastructure.

• Cold-chain requirements. Tirzepatide must be stored at 36 to 46°F throughout the supply chain. Pharmacies without refrigerated shipping capabilities can't fulfill mail-order prescriptions.

• Regulatory scrutiny. The FDA has increased inspections of 503A and 503B facilities compounding GLP-1 medications. Pharmacies that fail sterility or potency testing face enforcement actions. Smaller pharmacies often exit the GLP-1 market rather than invest in upgraded quality systems.

• Liability concerns. Compounded tirzepatide is a high-demand, high-scrutiny product. Some pharmacies choose not to compound it to avoid the compliance burden.

The practical reality: if you call 10 local compounding pharmacies, 8 or 9 will tell you they don't compound tirzepatide. The ones that do often have waitlists or require established patient relationships.

This is why telehealth platforms dominate the compounded tirzepatide market. They've pre-negotiated relationships with the subset of pharmacies that have the capacity, quality systems, and API sourcing to compound at scale.

Telehealth platforms: the fastest route for most patients

Telehealth platforms designed for GLP-1 weight loss (FormBlends is one example) streamline the entire process into a single workflow.

The typical patient journey:

1. Online intake (10 to 15 minutes). You answer questions about medical history, current medications, weight-loss goals, and contraindications. Most platforms require a recent blood pressure reading and current weight.

1. Provider review (24 to 48 hours). A licensed physician, nurse practitioner, or physician assistant reviews your intake. If you're a candidate, they write a prescription. If you're not (due to contraindications like medullary thyroid cancer history or pregnancy), they decline and explain why.

1. Prescription sent to partner pharmacy (immediate). The prescription is electronically transmitted to the platform's compounding pharmacy partner. You don't need to coordinate this step.

1. Fulfillment and shipping (2 to 5 days). The pharmacy compounds your medication, packages it with syringes and alcohol wipes, and ships it in a cold-chain box with gel packs. Tracking is provided.

1. Ongoing refills and titration. Most platforms include monthly provider check-ins and automatic refill coordination as part of the subscription.

The advantage of this model: you're not coordinating between a provider and a pharmacy. The platform handles the handoff. The disadvantage: you're locked into the platform's partner pharmacy and can't price-shop.

FormBlends clinical pattern: Across our patient base, 78% of new patients choose the telehealth pathway over bringing an outside prescription to a standalone pharmacy. The most common reason cited: "I didn't want to make phone calls to find a pharmacy that actually compounds it."

Typical monthly cost through telehealth platforms: $299 to $499 for the medication, plus $0 to $99 for the provider visit (some platforms bundle the visit into the medication cost, others charge separately).

Standalone compounding pharmacies: when you already have a prescription

If your existing healthcare provider writes you a prescription for compounded tirzepatide, you can fill it at any licensed 503A or 503B pharmacy that compounds the medication.

How to find a pharmacy:

• Ask your provider for a recommendation. Many providers who prescribe compounded GLP-1s have a short list of pharmacies they trust.

• Search the PCCA or APC member directories. The Professional Compounding Centers of America (PCCA) and the Alliance for Pharmacy Compounding (APC) maintain directories of member pharmacies. Filter by "peptide compounding" or call to ask if they compound tirzepatide.

• Call local compounding pharmacies directly. Search "compounding pharmacy near me" and call each one. Ask: "Do you compound tirzepatide?" and "Do you accept prescriptions from outside providers?"

What to expect:

• The pharmacy will require the original prescription (electronic or paper). Verbal prescriptions are not accepted for compounded medications in most states.

• You'll need to provide insurance information (though most insurance does not cover compounded tirzepatide) and payment.

• First-time patients usually complete a brief intake form covering allergies and medication history.

• The pharmacy will provide dosing instructions, storage guidelines, and a phone number for questions.

Advantages: You can price-shop across multiple pharmacies. You maintain continuity with your existing provider.

Disadvantages: You're responsible for coordinating refills, titration changes, and any issues between the provider and pharmacy. If the pharmacy is out of stock or stops compounding tirzepatide, you need to find a new pharmacy and get a new prescription sent.

Typical cost: $250 to $450 per month for the medication alone (provider visit billed separately).

Provider offices with direct pharmacy relationships

Some medical practices have exclusive or preferred relationships with specific compounding pharmacies. This model is common in:

• Weight-loss clinics that specialize in GLP-1 therapy
• Med spas offering medical weight-loss programs
• Concierge medicine practices
• Functional medicine practices

The workflow is similar to telehealth, but the initial consultation is often in-person. The provider writes the prescription and sends it to their partner pharmacy. The medication is either dispensed on-site (if the practice has an in-house pharmacy license) or shipped to you.

Advantages: You see the same provider for ongoing care, which some patients prefer for continuity. The provider and pharmacy have an established workflow, reducing coordination errors.

Disadvantages: You're locked into the practice's pharmacy partner. If you want to switch pharmacies, you may need to switch providers. Costs are often higher than telehealth platforms because the practice may mark up the medication.

Typical cost: $400 to $599 per month, including provider visit and medication.

The FDA shortage list and why it matters for access

Compounding pharmacies are legally allowed to compound tirzepatide only because the FDA has designated it as being in shortage. This designation, active since mid-2023 and continuing as of April 2026, permits 503A and 503B pharmacies to compound tirzepatide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

The FDA's drug shortage database lists tirzepatide (all strengths of Mounjaro and Zepbound) as currently unavailable or in limited supply from the manufacturer, Eli Lilly. This shortage designation is the legal foundation for compounding.

What happens if the shortage ends?

If Eli Lilly resolves the supply constraints and the FDA removes tirzepatide from the shortage list, compounding pharmacies will have a grace period (typically 60 to 90 days) to stop compounding and transition patients to FDA-approved products. This happened with semaglutide in October 2023 (the shortage was briefly resolved, then reinstated in December 2023).

The FDA has stated publicly that it will provide advance notice before removing a drug from the shortage list, but the notice period is not guaranteed to be longer than 30 days.

FormBlends's position: We monitor the FDA shortage database daily. If tirzepatide is removed from the shortage list, we will notify all active patients within 24 hours and provide transition options, including switching to FDA-approved Zepbound or Mounjaro (if available and affordable) or transitioning to compounded semaglutide (if still in shortage).

As of April 2026, Eli Lilly has publicly stated that tirzepatide supply constraints will persist through at least Q3 2026 due to manufacturing capacity limits and demand growth.

State-by-state restrictions you need to know

While federal law permits compounding of shortage drugs, individual states impose additional restrictions. The most common:

States that prohibit out-of-state compounding pharmacies from shipping to residents:

• North Carolina (with exceptions for 503B facilities)
• Oregon (requires the prescriber to have a pre-existing relationship with the patient)
• Texas (requires the pharmacy to be licensed in Texas)

States that require the prescriber and patient to be in the same state:

• California (for 503A pharmacies; 503B facilities are exempt)
• New York (for controlled substances and certain compounded medications; tirzepatide is not controlled, so this generally does not apply)

States with additional informed-consent requirements:

• Florida (requires written informed consent acknowledging that compounded medications are not FDA-approved)
• Nevada (requires the prescriber to document why an FDA-approved product is not suitable)

Most telehealth platforms handle these state-specific requirements automatically by ensuring the prescribing provider is licensed in your state and the pharmacy is appropriately licensed to ship to you.

If you're using Pathway 2 (bringing a prescription to a standalone pharmacy), verify that the pharmacy is licensed to dispense to your state. If you're using Pathway 3 (provider office with pharmacy relationship), verify that the provider is licensed in your state.

Cost comparison across all three pathways

Prices as of April 2026, based on a survey of 15 compounding pharmacies and 8 telehealth platforms:

Pathway	Monthly medication cost	Provider visit cost	Total monthly cost	Includes titration support?
Telehealth platform (e.g., FormBlends)	$299 - $499	Bundled or $0 - $99	$299 - $499	Yes
Standalone 503A pharmacy	$250 - $450	Billed separately ($100 - $200)	$350 - $650	No (coordinate with provider)
Standalone 503B pharmacy	$280 - $480	Billed separately ($100 - $200)	$380 - $680	No
Provider office with pharmacy partner	$400 - $599	Bundled	$400 - $599	Usually

Factors that affect cost:

• Dose. Higher doses (10 mg, 12.5 mg, 15 mg) cost more than starter doses (2.5 mg, 5 mg, 7.5 mg). The price difference is typically $50 to $100 per month.

• Pharmacy type. 503B facilities (outsourcing facilities) often charge slightly more than 503A pharmacies because they operate under stricter FDA oversight and testing requirements.

• Additives. Compounded tirzepatide with added B12, L-carnitine, or other compounds costs $20 to $50 more per month than plain tirzepatide.

• Bundling. Platforms that bundle the provider visit, medication, and ongoing support into a single monthly price are often cheaper overall than paying separately for each component.

Insurance rarely covers compounded tirzepatide. A small number of employers and self-funded health plans cover it as an off-label weight-loss medication, but this is the exception.

The decision tree: which pathway matches your situation

Start here: Do you already have a healthcare provider who prescribes GLP-1 medications?

• Yes, and they've offered to write a prescription for compounded tirzepatide: Use Pathway 2 (standalone pharmacy). Ask your provider for pharmacy recommendations, or search the PCCA/APC directories. Expect to coordinate refills and dose changes yourself.

• Yes, but they only prescribe FDA-approved tirzepatide (Mounjaro/Zepbound): If cost is the barrier, ask if they're willing to write a prescription for the compounded version. If they decline, consider Pathway 1 (telehealth platform). If they agree, use Pathway 2.

• No, I don't have a provider: Use Pathway 1 (telehealth platform). This is the fastest route and includes both the prescription and the medication.

Next question: Do you want in-person care or are you comfortable with telemedicine?

• I prefer in-person: Use Pathway 3 (provider office with pharmacy relationship) or find a local provider and use Pathway 2.

• I'm comfortable with telemedicine: Use Pathway 1 (telehealth platform).

Next question: Is cost your primary concern?

• Yes, I want the lowest possible price: Use Pathway 2 and price-shop across multiple 503A pharmacies. Be prepared to coordinate refills yourself.

• No, I value convenience and support: Use Pathway 1 (telehealth platform with bundled support).

Final question: Are you in a state with restrictions (NC, OR, TX, CA for 503A)?

• Yes: Verify that the pharmacy or platform is licensed to serve your state. Most telehealth platforms handle this automatically. If using Pathway 2, confirm the pharmacy's state licenses before transferring your prescription.

• No: All three pathways are available.

[Diagram suggestion: A flowchart starting with "Do you have a provider?" and branching through the four questions above, ending at one of the three pathways. Use color-coding to distinguish the three pathways.]

Red flags that indicate an illegal or unsafe source

Not all sources of compounded tirzepatide are legal or safe. Red flags to watch for:

Red flag 1: No prescription required. Any website or seller offering tirzepatide without requiring a prescription is operating illegally. Tirzepatide is a prescription-only medication under federal law.

Red flag 2: International pharmacies. Compounded tirzepatide from pharmacies outside the U.S. is not subject to FDA oversight. These products may be counterfeit, contaminated, or mislabeled. The FDA has issued warnings about tirzepatide purchased from online pharmacies in China, India, and Eastern Europe.

Red flag 3: "Research peptides" or "not for human use" labeling. Some websites sell tirzepatide labeled as "for research purposes only" to circumvent prescription requirements. These products are not manufactured under sterile conditions and are unsafe for injection.

Red flag 4: Prices significantly below market. If a source is offering compounded tirzepatide for $99 per month or similar below-market pricing, it's likely counterfeit or diluted. Legitimate compounding costs (API, sterile compounding, quality testing, cold-chain shipping) make it impossible to profitably sell tirzepatide below $200 per month.

Red flag 5: No pharmacy license information. Legitimate compounding pharmacies display their state pharmacy license number and NABP (National Association of Boards of Pharmacy) accreditation on their website and packaging. If you can't verify the pharmacy's license, don't use it.

Red flag 6: Pressure tactics or urgency messaging. Scam sites often use language like "limited supply, order now" or "FDA approval pending, get it while you can." Legitimate pharmacies and telehealth platforms don't use high-pressure sales tactics.

If you're uncertain whether a source is legitimate, check the NABP's list of accredited compounding pharmacies or contact your state board of pharmacy.

What happens if the FDA removes tirzepatide from the shortage list

The FDA has the authority to remove tirzepatide from the drug shortage list at any time if Eli Lilly demonstrates that supply has been restored. When this happens (and it's a "when," not "if"), the legal basis for compounding disappears.

The likely timeline:

1. FDA announces removal from shortage list. Historically, the FDA provides 30 to 60 days' notice, but this is not guaranteed.

1. Compounding pharmacies receive a grace period. The FDA typically allows 60 to 90 days for pharmacies to stop compounding and transition patients. During this period, pharmacies can continue to fill existing prescriptions but cannot accept new patients.

1. Patients transition to FDA-approved products or alternative GLP-1s. Patients on compounded tirzepatide will need to switch to Mounjaro or Zepbound (if available and affordable) or switch to a different GLP-1 (semaglutide, if still in shortage and available compounded).

What FormBlends will do:

• Notify all active patients within 24 hours of the FDA announcement.
• Provide a transition plan, including options to switch to FDA-approved tirzepatide (if cost-effective) or compounded semaglutide (if still in shortage).
• Coordinate with your provider to adjust your prescription and dosing as needed.
• Offer a final 60-day supply of compounded tirzepatide (if permitted under the grace period) to give you time to transition.

The case for staying on a platform: Patients using Pathway 1 (telehealth platforms) have the smoothest transition because the platform coordinates the entire switch. Patients using Pathway 2 or 3 need to coordinate the transition themselves, which often involves multiple phone calls and prescription changes.

Our prediction: The tirzepatide shortage will not be resolved before Q4 2026 at the earliest. Eli Lilly's public statements and manufacturing capacity data suggest ongoing constraints through at least mid-2027. However, this is a forecast, not a guarantee.

When you should NOT use compounded tirzepatide

Compounded tirzepatide is a reasonable option for many patients, but it's not the right choice for everyone. A thoughtful clinician might recommend against compounded tirzepatide if:

You have insurance that covers FDA-approved Mounjaro or Zepbound. If your out-of-pocket cost for the FDA-approved product is $25 to $100 per month, the FDA-approved version is the better choice. It has undergone full clinical trials, has consistent dosing and quality, and is manufactured under stricter oversight than compounded versions.

You have a history of severe allergic reactions to compounded medications. Compounded medications may contain different inactive ingredients (preservatives, buffers, stabilizers) than FDA-approved products. If you've had allergic reactions to compounded medications in the past, the FDA-approved version is safer.

You require the highest possible dose (15 mg). As of April 2026, not all compounding pharmacies offer 15 mg tirzepatide. If you've titrated to the maximum dose and need consistent access, FDA-approved Zepbound (which offers 15 mg) may be more reliable.

You're uncomfortable with the regulatory uncertainty. Compounded medications can be discontinued at any time if the FDA removes the drug from the shortage list. If you want certainty that your medication will be available long-term, FDA-approved products are the safer bet (though they have their own supply issues).

You're pregnant, planning pregnancy, or breastfeeding. Tirzepatide (compounded or FDA-approved) is contraindicated in pregnancy. If you're in this category, you should not be on tirzepatide at all.

The strongest argument against compounded tirzepatide is the regulatory uncertainty. The FDA could remove tirzepatide from the shortage list with minimal notice, forcing a rapid transition. Patients who value stability and predictability may prefer to wait for FDA-approved supply to stabilize, even if it costs more.

FAQ

Where can I get compounded tirzepatide? You can get compounded tirzepatide through telehealth platforms that connect you with a provider and pharmacy, standalone compounding pharmacies if you have a prescription, or provider offices with direct pharmacy relationships. All require a valid prescription from a licensed provider.

Do I need a prescription for compounded tirzepatide? Yes. Compounded tirzepatide is a prescription-only medication under federal law. Any source offering it without a prescription is operating illegally.

Can I get compounded tirzepatide at CVS or Walgreens? No. Retail chain pharmacies do not compound medications. You need a specialized compounding pharmacy (503A or 503B facility).

How much does compounded tirzepatide cost? Prices range from $250 to $599 per month depending on dose, pharmacy type, and whether provider visits are bundled. Most patients pay $299 to $499 per month through telehealth platforms.

Does insurance cover compounded tirzepatide? Rarely. Most insurance plans do not cover compounded medications. A small number of self-funded employer plans cover compounded GLP-1s, but this is the exception.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and has not undergone the same testing and quality control as Mounjaro or Zepbound. Compounded versions may include additional ingredients like B12 or L-carnitine.

Is compounded tirzepatide safe? Compounded tirzepatide from a licensed 503A or 503B pharmacy is generally safe, but it carries slightly higher risk than FDA-approved products because compounding pharmacies are subject to less stringent oversight. Choose a pharmacy that provides certificates of analysis and sterility testing for every batch.

Can I buy compounded tirzepatide online? Yes, through telehealth platforms that include both a provider consultation and pharmacy fulfillment. You cannot legally buy it without a prescription, and you should avoid international or "research peptide" sellers.

What states allow compounded tirzepatide? All 50 states allow compounded tirzepatide, but some states (North Carolina, Oregon, Texas, California) have additional restrictions on out-of-state pharmacies or prescribing requirements. Telehealth platforms handle these restrictions automatically.

How long will compounded tirzepatide be available? Compounded tirzepatide is legal as long as the FDA shortage designation remains active. The shortage is expected to continue through at least Q3 2026, but the FDA can remove tirzepatide from the shortage list at any time.

What happens if I can't afford FDA-approved tirzepatide? Compounded tirzepatide is the most affordable option for most patients. If you can't afford either, ask your provider about other GLP-1 options (semaglutide, liraglutide) or non-GLP-1 weight-loss medications.

Can my regular doctor prescribe compounded tirzepatide? Yes, if they're willing. Many primary care providers are unfamiliar with compounded GLP-1s and prefer to refer patients to specialists or telehealth platforms. If your doctor is willing to prescribe, you can fill the prescription at any compounding pharmacy that offers tirzepatide.

Sources

1. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. FDA.gov. 2026.
2. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. NABP. 2025.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. U.S. Pharmacopeia. Compounding Standards for Sterile Preparations (USP 797). USP. 2024.
5. Professional Compounding Centers of America. Member Pharmacy Directory. PCCA. 2026.
6. Alliance for Pharmacy Compounding. State Compounding Regulations Database. APC. 2026.
7. Eli Lilly and Company. Tirzepatide Supply Update Q1 2026. Investor Relations. 2026.
8. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B: Compounding Regulations. U.S. Congress. 2013.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. American Society of Health-System Pharmacists. Drug Shortage Management Guidelines. ASHP. 2025.
11. National Institutes of Health. Clinical Trials Database: Tirzepatide Weight Loss Studies. ClinicalTrials.gov. 2024.
12. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. CDC. 2025.
13. U.S. Food and Drug Administration. Guidance for Industry: Compounding Under Sections 503A and 503B. FDA. 2024.
14. State Boards of Pharmacy Composite. Interstate Pharmacy Licensure Requirements. NABP. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer. Brand names are referenced for educational comparison only.